Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Rogge

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|October 8, 2010
Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjectsZhaoyang Li, Christopher TenHoor, Thomas Marbury, et al.
Journal of Clinical Pharmacology|November 25, 2024
Sentinel Dosing-Time for a Risk-Based Approach?Peter L Bonate, Mark Rogge, Jean-Michel Gries, et al.
Clinical Pharmacology and Therapeutics|April 24, 2003
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysisHoward Lee, Hui C Kimko, Mark Rogge, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 7, 2002
Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosingPauline L Martin, Sujata Vaidyanathan, Joan Lane, et al.
Clinical Pharmacology and Therapeutics|March 28, 2022
Asia-Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status QuoKarthik Venkatakrishnan, Neeraj Gupta, Patrick F Smith, et al.
Journal of Clinical Pharmacology|June 27, 2014
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal functionPing He, Doug Kerr, Thomas Marbury, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 17, 2024
Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasoneYuki Otani, Yunqi Zhao, Guanyu Wang, et al.
Journal of Clinical Pharmacology|June 6, 2015
Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studiesLichuan Liu, Akintunde Bello, Mark J Dresser, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 1, 2026
Autosomal Dominant Tubulointerstitial Kidney Disease Clinical Trial Simulator: Case Reports of Model-Informed Drug DevelopmentShyam S Ramesh, Mark Rogge, Jongjin Kim, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 24, 2025
Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progressionShyam S Ramesh, Mark Rogge, Kendrah O Kidd, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|October 8, 2010
Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjectsZhaoyang Li, Christopher TenHoor, Thomas Marbury, et al.
Journal of Clinical Pharmacology|November 25, 2024
Sentinel Dosing-Time for a Risk-Based Approach?Peter L Bonate, Mark Rogge, Jean-Michel Gries, et al.
Clinical Pharmacology and Therapeutics|April 24, 2003
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysisHoward Lee, Hui C Kimko, Mark Rogge, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 7, 2002
Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosingPauline L Martin, Sujata Vaidyanathan, Joan Lane, et al.
Clinical Pharmacology and Therapeutics|March 28, 2022
Asia-Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status QuoKarthik Venkatakrishnan, Neeraj Gupta, Patrick F Smith, et al.
Journal of Clinical Pharmacology|June 27, 2014
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal functionPing He, Doug Kerr, Thomas Marbury, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 17, 2024
Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasoneYuki Otani, Yunqi Zhao, Guanyu Wang, et al.
Journal of Clinical Pharmacology|June 6, 2015
Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studiesLichuan Liu, Akintunde Bello, Mark J Dresser, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 1, 2026
Autosomal Dominant Tubulointerstitial Kidney Disease Clinical Trial Simulator: Case Reports of Model-Informed Drug DevelopmentShyam S Ramesh, Mark Rogge, Jongjin Kim, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 24, 2025
Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progressionShyam S Ramesh, Mark Rogge, Kendrah O Kidd, et al.
Pageof 3